JCR Pharmaceuticals Co.,Ltd. (4552.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 517.00

From 52W high−34.23%

Volume352300.00

Market capJPY 62.82B

P/E (TTM)76.6x

P/S (TTM)1.5x

Div yield3.88%

Key dataSep 18, 2026

Open

JPY 517.00

From 52W high

−34.23%

Volume

352300.00

Market cap

JPY 62.82B

ValuationView details →

P/E (Fwd)

35.2x

EV/EBITDA

23.8x

P/E (TTM)

76.6x

RSI (14)

48.8

MomentumView details →

1D Return

+1.18%

YTD Return

−27.53%

ValuationView details →

P/E (Fwd)

35.2x

P/E (TTM)

76.6x

EV/EBITDA

23.8x

EV/Sales

2.6x

P/S (TTM)

1.5x

P/B (TTM)

1.5x

ProfitabilityView details →

Gross Margin

74.87%

Net Margin

5.40%

EBITDA Margin

7.72%

ROE (TTM)

4.60%

ROA (TTM)

1.99%

Asset Turnover

0.36x

GrowthView details →

Revenue YoY

+21.91%

EPS YoY

+146.54%

FCF YoY

—

Revenue CAGR 3Y

+5.49%

EPS CAGR 3Y

−16.18%

EBITDA YoY

—

MomentumView details →

1D Return

+1.18%

YTD Return

−27.53%

1Y Return

−19.63%

RSI (14)

48.8

vs 50D SMA

+0.35%

vs 200D SMA

−10.99%

Capital & dividendView details →

Debt/Equity

1.06x

Current Ratio

1.16x

Quick Ratio

1.12x

Div Yield

3.88%

Div Rate

JPY 20.00

Div Growth 1Y

+0.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

38.52B

Net Income (TTM)

−2.07B

Op. CF (TTM)

—

Next earningsOct 28, 2026 →

Latest newsMore news →

Acumen Pharmaceuticals exercised its exclusive option to develop therapeutic candidates for Alzheimer's disease using JCR Pharmaceuticals' J-Brain Cargo technology platform.95d ago

Acumen Pharmaceuticals nominated two development candidates, ACU301 and ACU401, in its Enhanced Brain Delivery program for Alzheimer's disease treatment.96d ago

Similar companies

ASKA Pharmaceutical Holdings Co.,Ltd.4886.T KYORIN Pharmaceutical Co.,Ltd.4569.T SanBio Company Limited4592.T Heartseed Inc.219A.T TAUNS Laboratories,Inc.197A.T EIKEN CHEMICAL CO.,LTD.4549.T Find similar companies →

Latest newsMore news →

Acumen Pharmaceuticals exercised its exclusive option to develop therapeutic candidates for Alzheimer's disease using JCR Pharmaceuticals' J-Brain Cargo technology platform.95d ago Acumen Pharmaceuticals nominated two development candidates, ACU301 and ACU401, in its Enhanced Brain Delivery program for Alzheimer's disease treatment.96d ago